BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Immunology

Akeso Reports Durable Long Term Survival Benefit Of Cadonilimab In Advanced Cervical Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the latest long-term survival analysis data from the China pivotal registrational Phase II ...

March 06, 2026 | Report

Ono Pharmaceutical And Congruence Expand Research Alliance Into Neurology And Immunology

Expanded collaboration continues to leverage Congruence's proprietary computational drug discovery engine, Revenir™ to deliver Development Candi...

March 04, 2026 | News

Pfizer And Astellas Report Strong Phase III EV 304 Results For PADCEV Plus Pembrolizumab In MIBC

In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with ove...

March 02, 2026 | News

Optellum Secures TGA Approval In Australia For AI Powered Virtual Nodule Clinic

Optellum, the leading AI-enabled solution for earlier lung cancer detection, is thrilled to announce that it has received Therapeutic Goods Administration ...

March 02, 2026 | News

WuXi XDC And Earendil Labs Forge Strategic Alliance To Advance Next Generation AI Designed ADCs

WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializin...

March 02, 2026 | News

Astellas And Vir Biotechnology Forge Global Partnership To Advance VIR 5500 In Prostate Cancer

- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - - Astellas to lead commerci...

February 25, 2026 | News

AVEO Oncology Selects Ficlatuzumab Dose for Phase 3 FIERCE-HN Trial in Head and Neck Cancer

– Global enrollment continues in the Phase 3 registrational studyfollowing the planned first interim analysis for patients with HPV-negati...

February 24, 2026 | News

ImmunityBio Partners With Accord Healthcare To Expand ANKTIVA Access Across Europe

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, announced a partnership with Accord Healthcare to provide access to ANKTI...

February 23, 2026 | News

ANKTIVA Plus BCG Secures European Commission Authorization As First Immunotherapy For BCG Unresponsive NMIBC

ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe for non-muscle invasive blad...

February 20, 2026 | News

Telix Submits European Marketing Application For TLX101 Px To Expand Glioma PET Imaging Access

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that it has submitted a marketing authorization application (MAA) in Europe ...

February 19, 2026 | News

Bio Techne Corporation Announces CE IVD Marking For Ella Benchtop Immunoassay Platform In European Union

Ella benchtop instrument is now CE-IVD marked and available for sale in the EU Enables diagnostic assay developers to leverage a simplified platform tha...

February 18, 2026 | News

Eli Lilly And Company Reports Statistically Significant Event Free Survival Benefit With Selpercatinib In Early Stage RET Fusion Positive NSCLC

Selpercatinib demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or deat...

February 18, 2026 | News

Innovent Advances IBI354 Into Pivotal Phase Three Trial For HER2 Positive Advanced Breast Cancer

Innovent Biologics, Inc. ("Innovent",HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medi...

February 16, 2026 | News

Jyong Biotech Strengthens Preventive Medicine Position With Positive Phase II Data And Asian Expansion

Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer prevention, discovery of novel lipid-modul...

February 16, 2026 | News

Stay Connected